H
Hangzhou Xingsai Ruizhen Biotechnology
Cell therapy and regenerative medicine development platform
About Hangzhou Xingsai Ruizhen Biotechnology
Hangzhou Xingsai Ruizhen Biotechnology Co., Ltd. (Celregen) is a platform-based company specializing in cell therapy and regenerative medicine. Founded in July 2022, the company was incubated by the New Drug Innovation Fund of Fosun Health Capital. Celregen has its headquarters in Hangzhou and a research and development center in Shanghai.
The company employs a business model that combines in-licensing of external technologies with its own in-house research and development. A key partnership was established in September 2022 with the Japanese startup Cellusion Inc., granting Celregen exclusive rights to develop, manufacture, and commercialize CLS001 in Greater China (mainland China, Hong Kong, Macau, and Taiwan). CLS001 is an iPSC-derived corneal endothelial cell substitute designed to treat bullous keratopathy, addressing the significant shortage of donor corneas. The agreement has a potential value exceeding $100 million, inclusive of upfront payments, milestones, and royalties.
Celregen's technology platform is centered on induced pluripotent stem cells (iPSCs). It encompasses rapid iPSC reprogramming, a proprietary CRISPR/Cas12b-based gene-editing system, and bioinformatics-guided differentiation techniques. This integrated platform supports the entire R&D process for iPSC-derived products. Beyond its lead program in corneal regeneration (CRG-101/CLS001), the company is also developing therapies for insulin-dependent diabetes (CRG-002) and exploring applications in tumor therapy through stem cell-derived CAR-NK treatments. The company's focus is on creating off-the-shelf allogeneic cell therapies for conditions with high unmet clinical needs.
In August 2022, Celregen secured 45 million yuan (approximately $6.67 million) in a seed funding round from Fosun Health Capital's New Drug Innovation Fund.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Diabetes, Ophthalmology, Crispr, Cell Therapy, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Mar 2025 | $14M | $55M | Fosun Health Capital · SCI Advanced Technology Fund | ↗ |
| SEED✓Equity / VC | Sep 2024 | $2.8M | $11M | SCI Advanced Technology Fund · Fosun Health Capital | ↗ |
Growth signals
Latest recorded traffic for Hangzhou Xingsai Ruizhen Biotechnology is 1K monthly website visits, up 88.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hangzhou Xingsai Ruizhen Biotechnology in its local ecosystem
The Hangzhou Xingsai Ruizhen Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
SCI Advanced Technology Fund- FCFosun Health Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Xingsai Ruizhen Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Xingsai Ruizhen Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








